Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 7/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 6/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | STK4 | Q13043 | 2/20 | 0.33 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.33 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918523 | 0.84 | MAPT (0.41) | CSF1REGFRHDAC2HDAC8TTBK1 | |
| SCHEMBL9918545 | 0.84 | CSF1R (0.46) | CSF1RLMNA | |
| SCHEMBL9921764 | 0.84 | MEN1 (0.40) | CSF1R | |
| SCHEMBL9918539 | 0.83 | CSF1R (0.36) | CSF1REGFRERBB2AURKARPS6KB1 | |
| SCHEMBL9918520 | 0.82 | CSF1R (0.32) | CSF1REGFRSTK4 | |
| SCHEMBL9918517 | 0.77 | RET (0.35) | EGFRTTBK1TTBK2 | |
| SCHEMBL9918540 | 0.76 | EGFR (0.42) | CSF1REGFRERBB2 | |
| SCHEMBL12833307 | 0.75 | LRRK2 (0.43) | CSF1RTTBK1TTBK2 | |
| SCHEMBL12833305 | 0.74 | NOTUM (0.40) | LMNATTBK1TTBK2 | |
| SCHEMBL9918529 | 0.71 | JAK1 (0.34) | TTBK1TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | CSF1R 410/4885CYP2B6 1392/4885EGFR 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.